operative tumour burden. 5 No medical therapy is able to compensate for an inadequate surgical procedure; therefore, patients suspected of ovarian cancer should be referred to a specialised hospital site.
In 1996, the Gynecology Oncology Group (GOG) study 111 6 showed that cisplatin in combination with paclitaxel was superior to cisplatin and cyclophosphomide with respect to disease-free survival (DFS) and overall survival (OAS). This study was conducted in patients who had received a suboptimal tumour reduction surgery. DFS and OAS were significantly prolonged in those patients who received cisplatin and paclitaxel compared with patients who received cisplatin and cyclophosphomide (18 versus 12.9 months and 37 versus 24 months, respectively). Based on these results, three prospective randomised trials proved the efficacy of paclitaxel in combination with platin derivates. [7] [8] [9] The combination of cisplatin, paclitaxel, carboplatin and paclitaxel showed similar values for time to progression and OAS. In contrast, the latter combination was less neurotoxic than the cisplatin-based regimen. Therefore, quality of life is significantly improved by using carboplatin instead of cisplatin. 10 Another advantage in favour of the carboplatin/paclitaxel combination is that this regimen can be administered in an outpatient setting. Therefore, today's standard primary chemotherapy in ovarian cancer treatment is the combination of carboplatin and paclitaxel, providing the best ratio of benefits to side effects. 11 Although this gold standard has been improving OAS significantly, the prognosis of ovarian cancer remains poor due the occurrence of chemotherapy resistance. One option to improve the efficacy of the standard treatment is the incorporation of non-cross-resistant cytotoxic drugs in addition to carboplatin and paclitaxel. Several attempts have been undertaken over the past few years with different drugs. The addition of epirubicine did not prolong progression-free survival (PFS) or OAS, but did increase haematological and non-haematological toxicities. 12, 13 Also, the combination of carboplatin, paclitaxel and topotecan as sequential single agents did not improve outcome. 14, 15 Incorporating liposomal pegylated doxorubicine and gemcitabine did not benefit patient survival. 16 So far, all attempts to further improve efficacy by adding a third non-cross-resistant conventional cytotoxic agent (e.g. 
abdominal pain, neurotoxicity). Even in experienced cancer centres, only
42% received the IP regimen as planned. Eight per cent of the patients did not obtain IP chemotherapy at all, and in 34% of the patients only one to two cycles of IP chemotherapy were given. However, interpretation of the results is difficult. One point of criticism is that different dosages of cisplatin were used (75 versus 100mg/m 2 ). Also, the additional application of paclitaxel on day eight raises the question of whether it would be useful to employ a dose-dense schema rather than giving chemotherapy IP. Additionally, it was not an intention-to-treat analysis. No data about second-line treatment are published; this fact seems to be very important since it is well known that second-line treatment has an impact on survival. Thus, this regimen has not been adopted as a standard of care.
Future Perspectives
The future of cancer therapy may lie in identifying biological dependencies of cancer cells that can be specifically targeted. Within the last few years, more and more specific antibodies and small molecules have become available for targeted therapy. For ovarian cancer patients, the correct therapeutic intervention could be a combination of carboplatin and paclitaxel plus a small-molecule drug. Targeting tumourinduced neoangiogenesis may be one option.
The humanised vascular endolethial growth factor (VEGF) antibody bevacizumab shows clinical responses in heavily pre-treated ovarian cancer patients. [18] [19] [20] [21] The NCT00129727 trial, in which patients will receive carboplatin, paclitaxel and bevacizumab, is currently recruiting. In this trial, bevacizumab will be given every three weeks for a year. In a phase II study, erlotinib showed marginal activity but was well tolerated.
Interestingly, the survival rate correlated significantly with the skin rush grade induced by erlotinib; patients with higher grades of skin rushes survived for a longer time. 22 Erlotinib will also be investigated in a phase III clinical trial, given as a maintenance therapy after primary chemotherapy. In phase I clinical trials, the anti-idiotypic antibody abagovomab (CA-125 antigen) in patients with recurrent ovarian cancer was found to be safe to be administered and was also well tolerated. 23, 24 Imatinib is a small-molecule drug that inhibits tyrosine kinases. It is used in haematological malignancies and in patients suffering from gastrointestinal stromal tumours (GIST). The recently conducted Southwest Oncology Group (SWOG) S0211 trial using imatinib in recurrent platinum-resistant ovarian cancer did not show a markedly improved response rate. 25 Using the small-molecule drug gefitinib in epithelial ovarian cancer also did not show a clinical response. However, at the molecular level, a decrease in target phosphorylation was observed. 26 Although these data are preliminary, they suggest that the combination of conventional chemotherapy and targeted therapy may increase chemotherapy responses, prolong DFS and, therefore, improve the prognosis of ovarian cancer.
Conclusion
Today, the combination of radical cyto-reductive surgery and chemotherapy with carboplatin and paclitaxel is the standard treatment for advanced ovarian cancer patients. Much hope is pinned on targeted therapies utilising novel molecular drugs, and several phase III trials with these substances have already begun worldwide. ■
